Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction

L. Januzzi, James; F. Prescott, Margaret; Butler, Javed; Michael Felker, G.; S. Maisel, Alan; McCague, Kevin; Camacho, Alexander; L. Piña, Ileana; A. Rocha, Ricardo; M. Shah, Amil; Williamson, Kristin; D. Solomon, Scott; the PROVE-HF Investigators, for

doi:10.1001/jama.2019.12821

Public

Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction

Published in JAMA • Sep 2, 2019

Authors:

James L. Januzzi

Margaret F. Prescott

Javed Butler

Abstract

IMPORTANCE: In patients with heart failure and reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations. The effect of sacubitril-valsartan on cardiac remodeling is uncertain. OBJECTIVE: To determine whether N...

Subject

Medicine

Sacubitril

Valsartan

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!